GLPG2222: Clinical Trials

3 trials of GLPG2222, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed. 3 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 13Completed 3

Follow GLPG2222: new trials by email Literature Review of GLPG2222 trials Research Report on GLPG2222

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Assess How Food Affects the Safety and Pharmacokinetics of Galicaftor and Navocaftor
Galicaftor, Navocaftor - Healthy Volunteers
Phase 1CompletedAbbVie242022-09-272023-01-17
A Study Looking at the Safety, Tolerability and Efficacy of the Combination of the Study Drugs GLPG2451 and GLPG2222 With or Without GLPG2737 in Patients With Cystic Fibrosis.
GLPG2451 dose regimen A, GLPG2451 dose regimen B, GLPG2222 - Cystic Fibrosis
Phase 1CompletedLakefront Biotherapeutics NV102018-05-312019-04-08
First-in-Human Single and Multiple Dose of GLPG2222
GLPG2222 single dose, Placebo single dose, GLPG2222 multiple doses - Healthy
Phase 1CompletedLakefront Biotherapeutics NV402016-01-012016-07-29

Conditions studied

Cystic Fibrosis (1)

Sponsors

Lakefront Biotherapeutics NV (2)  ·  AbbVie (1)

Countries

Belgium (2)  ·  Bulgaria (1)  ·  Germany (1)  ·  Greece (1)  ·  Netherlands (1)  ·  Serbia (1)  ·  Sweden (1)  ·  United Kingdom (1)  ·  United States (1)

Top investigators

Kirsteen Donaldson, MD (1)  ·  Olivier Van de Steen, MD MBA (1)

NIH funding

2015 (1), 2017 (1)